DE69426452T2 - Fibrinogen receptor antagonisten - Google Patents

Fibrinogen receptor antagonisten

Info

Publication number
DE69426452T2
DE69426452T2 DE69426452T DE69426452T DE69426452T2 DE 69426452 T2 DE69426452 T2 DE 69426452T2 DE 69426452 T DE69426452 T DE 69426452T DE 69426452 T DE69426452 T DE 69426452T DE 69426452 T2 DE69426452 T2 DE 69426452T2
Authority
DE
Germany
Prior art keywords
receptor antagonists
fibrinogen receptor
fibrinogen
formula
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69426452T
Other languages
English (en)
Other versions
DE69426452D1 (de
Inventor
D Hartman
D Prugh
Wasyl Halczenko
Melissa Egbertson
Nathan Ihle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69426452D1 publication Critical patent/DE69426452D1/de
Application granted granted Critical
Publication of DE69426452T2 publication Critical patent/DE69426452T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
DE69426452T 1993-08-09 1994-08-04 Fibrinogen receptor antagonisten Expired - Fee Related DE69426452T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/103,846 US5397791A (en) 1993-08-09 1993-08-09 Fibrinogen receptor antagonists
PCT/US1994/008865 WO1995004531A1 (en) 1993-08-09 1994-08-04 Fibrinogen receptor antagonists

Publications (2)

Publication Number Publication Date
DE69426452D1 DE69426452D1 (de) 2001-01-25
DE69426452T2 true DE69426452T2 (de) 2001-06-21

Family

ID=22297323

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69426452T Expired - Fee Related DE69426452T2 (de) 1993-08-09 1994-08-04 Fibrinogen receptor antagonisten

Country Status (9)

Country Link
US (1) US5397791A (de)
EP (1) EP0714295B1 (de)
JP (1) JPH09501435A (de)
AT (1) ATE198202T1 (de)
AU (1) AU683294B2 (de)
CA (1) CA2168581A1 (de)
DE (1) DE69426452T2 (de)
ES (1) ES2152328T3 (de)
WO (1) WO1995004531A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US6623981B2 (en) * 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
PL1682537T3 (pl) * 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulatory adhezji komórkowej
CA2609053C (en) * 2005-05-17 2017-04-25 Sarcode Corporation Compositions and methods for treatment of eye disorders
EP3797775A1 (de) 2007-10-19 2021-03-31 Novartis AG Zusammensetzungen und verfahren zur behandlung von diabetischer retinopathie
EP3632444A3 (de) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topische lfa-1-antagonisten zur verwendung in der lokalen behandlung von immunerkrankungen
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN104797574B (zh) 2012-07-25 2019-11-22 原生质生物科学股份有限公司 Lfa-1抑制剂及其多晶型物
US9487485B2 (en) 2013-02-28 2016-11-08 Takeda Pharmaceutical Company Limited Method for producing sulfonyl chloride compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313947A (en) * 1974-06-24 1982-02-02 Otsuka Pharmaceutical Co., Ltd. Platelet aggregation inhibiting 2-oxyindoles, their compositions and method of use
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
FR2334358A1 (fr) * 1975-12-12 1977-07-08 Sogeras Nouveaux medicaments derives de l'indole
US4064125A (en) * 1976-10-29 1977-12-20 E. R. Squibb And Sons, Inc. Substituted amides having antiinflammatory activity
DE3065026D1 (en) * 1979-05-23 1983-11-03 Beecham Wuelfing Gmbh & Co Kg Phenylsulphonamide derivatives, a process for their preparation and their use as medicines
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
US5037808A (en) * 1988-07-20 1991-08-06 Monsanto Co. Indolyl platelet-aggregation inhibitors
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5256812A (en) * 1989-01-31 1993-10-26 Hoffmann-La Roche Inc. Carboxamides and sulfonamides
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
NZ234264A (en) * 1989-06-29 1993-05-26 Warner Lambert Co N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives, and pharmaceutical compositions
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
IL99539A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.

Also Published As

Publication number Publication date
DE69426452D1 (de) 2001-01-25
AU683294B2 (en) 1997-11-06
EP0714295A4 (de) 1996-07-10
US5397791A (en) 1995-03-14
JPH09501435A (ja) 1997-02-10
EP0714295A1 (de) 1996-06-05
ATE198202T1 (de) 2001-01-15
ES2152328T3 (es) 2001-02-01
AU7521194A (en) 1995-02-28
CA2168581A1 (en) 1995-02-16
WO1995004531A1 (en) 1995-02-16
EP0714295B1 (de) 2000-12-20

Similar Documents

Publication Publication Date Title
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
MX9101311A (es) Antagonistas receptores de fibrinogeno
DE69530571D1 (de) Bicyclische fibrinogenantagonisten
DE69417576T2 (de) Zementzusatzmittel
FI961804A (fi) Endoteliinireseptoriantagonistit
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
DE69425655T2 (de) Antagonisten des fibrinogenrezeptors
MX9100717A (es) Antagonistas de la bradiquinina
DK0699069T3 (da) Endothelinreceptorantagonister
KR960700722A (ko) 피브리노겐 수용체 길항제(Fibrinogen receptor antagonists)
ATE198202T1 (de) Fibrinogen receptor antagonisten
KR950703530A (ko) 5-HT4 길항제(5-HT4 Antagonists)
KR950700305A (ko) 칼슘 통로 길항제로서 아자바이사이클로 화합물(Azabicyclo compounds as calcium channel antagonists)
NO930262L (no) Bombesin-antagonister
FI943359A (fi) Atsasykliset-heterosykliset yhdisteet angiotensiini II reseptoriantagonisteina
ATE208764T1 (de) Isazole derivate als fibrinogen-rezeptor- antagonisten
FI922124A (fi) Azabicykloamider och -estrar som 5-ht3-receptorantagonister.
FI930108A (fi) Imidazopyridin-paf-antagonister
LV10425A (lv) Fibrinogena receptoru antagonisti
LV5746B4 (lv) Jauni sulfonamidu fibrinogena receptora antagonisti
HU9402431D0 (en) Novel sulfonamide fibrinogen receptor antagonists
ZA917694B (en) Novel fibrinogen receptor antagonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee